AVEANNA HEALTHCARE HOLDINGS ANNOUNCES PRELIMINARY THIRD QUARTER FINANCIAL RESULTS Atlanta, Georgia (October 21, 2025) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced certain preliminary financial results for the three-month period ended September 27, 2025. For the three-month period ended September 27, 2025, we expect to report: Preliminary Financial Data Our consolidat ...

Financial Performance - For Q3 2025, GEO reported total revenues of $682.3 million, up from $603.1 million in Q3 2024, representing a 13.2% increase[7]. - Net income attributable to GEO for Q3 2025 was $173.9 million, or $1.24 per diluted share, compared to $26.3 million, or $0.19 per diluted share, in Q3 2024[3]. - Adjusted EBITDA for Q3 2025 was $120.1 million, slightly up from $118.6 million in Q3 2024[7]. - Revenues for Q3 2025 reached $682,341, an increase from $603,125 in Q3 2024, representing a growth of approximately 13.1%[54]. - Net income attributable to The GEO Group, Inc. for YTD 2025 was $222,606, compared to $16,475 in YTD 2024, showing a significant increase[54]. - Operating income for Q3 2025 was $40,700, down from $82,371 in Q3 2024, reflecting a decrease of approximately 50.6%[54]. - Net Income for Q3 2025 was $173,922,000, a significant increase from $26,289,000 in Q3 2024, representing a growth of 560%[56]. - Adjusted EBITDA for Q3 2025 reached $120,093,000, slightly up from $118,636,000 in Q3 2024, indicating a 1.2% increase[56]. - The company projects FY 2025 Net Income Attributable to GEO to be between $254,000,000 and $259,000,000[59]. - Adjusted EBITDA for FY 2025 is expected to be between $455,000,000 and $465,000,000[59]. - The projected Net Income Attributable to GEO per diluted share for FY 2025 is estimated to be between $1.81 and $1.85[59]. Debt and Financial Guidance - GEO has reduced its net debt by approximately $275 million, with net debt totaling around $1.4 billion at the end of Q3 2025[26]. - The updated financial guidance for Q4 2025 anticipates GAAP Net Income in the range of $0.23 to $0.27 per diluted share on revenues of $651 million to $676 million[21]. - Total Debt, Net is projected to be $1,500,000,000 for FY 2025[59]. - Interest expense for YTD 2025 was $122,582, down from $147,437 in YTD 2024, reflecting a decrease of approximately 16.8%[54]. - The company anticipates a total leverage ratio of 3.3 for FY 2025[59]. - Net debt is defined as gross principal debt less cash from restricted subsidiaries, with a focus on reducing outstanding debt to strengthen capital structure[39]. Contracts and Revenue Growth - The company entered into new or expanded contracts representing over $460 million in new annualized revenues expected to normalize in 2026, the largest amount in its history[8]. - The company expects to generate over $300 million in incremental annualized revenues from five newly contracted facilities at full occupancy in 2026[12]. - A new two-year contract for electronic monitoring services under the ISAP program was awarded, valued at over $1 billion, with anticipated cost savings of $2 million to $3 million per quarter starting in 2026[20]. Share Repurchase and Capital Expenditures - GEO repurchased approximately 1.97 million shares for $41.6 million during Q3 2025, with a total share repurchase authorization increased to $500 million[27]. - The company has authorized a $500 million share repurchase program to enhance shareholder value[49]. - Capital Expenditures for FY 2025 are expected to be between $200,000,000 and $205,000,000[59]. Assets and Legal Challenges - The total assets as of September 30, 2025, were $3,809,273, up from $3,632,080 as of December 31, 2024, indicating a growth of approximately 4.9%[51]. - The company reported a contingent litigation reserve of $37,600 for Q3 2025, indicating ongoing legal challenges[54]. - The company aims to capture additional growth opportunities and improve company-wide occupancy rates at its facilities[49]. Losses and Adjusted Income - The company reported a loss on asset divestitures of $232,381,000 in Q3 2025[56]. - Adjusted Net Income for Q3 2025 was $34,970,000, compared to $29,052,000 in Q3 2024, reflecting an increase of 20.5%[56].

Exhibit 99.1 Planet Fitness, Inc. Announces Third Quarter 2025 Results System-wide same club sales increased 6.9% Raises 2025 full-year growth outlook Repurchased approximately $100M of its shares Hampton, NH, November 6, 2025 - Today, Planet Fitness, Inc. (NYSE: PLNT) reported financial results for its third quarter ended September 30, 2025. Third Quarter Fiscal 2025 Highlights "We are making significant progress in executing on our long-term strategy, as highlighted by our strong financial performance dur ...

Business Growth and Strategy - For the nine months ended September 30, 2025, 68% of refinancing volumes came from new loans and 16% of total transaction volumes came from new customers[123]. - The company is focused on significantly growing its small-balance multifamily lending platform, which involves a high volume of transactions with smaller loan balances[134]. - The company purchased the remaining 25% interest in Zelman, enhancing its housing market research and investment banking capabilities[139]. - The company has increased the number of property sales brokers and expanded its geographical reach, covering many major markets in the United States[138]. - The company provides a comprehensive range of commercial real estate finance products, including Agency lending and debt brokerage services[128]. - The company has established long-term relationships with the Agencies and institutional investors, enabling it to offer a broad range of loan products[128]. Financial Performance - Total revenues for the three months ended September 30, 2025, increased by 16% to $337,675,000 compared to $292,304,000 in 2024[177]. - Net income for the three months ended September 30, 2025, rose by 16% to $33,452,000 from $28,802,000 in 2024[177]. - The operating margin improved to 14% in Q3 2025, compared to 13% in Q3 2024, while return on equity increased to 8% from 7% year-over-year[173]. - For the nine months ended September 30, 2025, total revenues increased by 13% to $894,282,000 compared to $791,039,000 in 2024[183]. - Net income for the nine months ended September 30, 2025, was $93,630,000, a decrease of 23% from $121,197,000 in 2024[230]. Revenue Streams - Loan origination and debt brokerage fees increased by 33% to $97,845,000, driven by higher total debt financing volumes[177]. - Servicing fees rose to $85,189,000, reflecting a 4% increase from $82,222,000 in the previous year[192]. - Investment management fees decreased by 42% to $23,437,000, primarily due to a decline in asset management fees from LIHTC operations[183]. - Other revenues for the three months ended September 30, 2025, increased by 40% to $29,024,000, up from $20,753,000[192]. Expenses and Costs - Total expenses for the nine months ended September 30, 2025, rose by 12% to $796,727,000, driven by increases in personnel and operating expenses[184]. - Personnel expenses increased by 22% to $177,418,000, primarily due to higher commission costs and increased headcount[178]. - Income tax expense for the three months ended September 30, 2025, increased by 42% to $12,516,000, influenced by a 22% rise in income from operations[181]. Market Conditions and Risks - The company is subject to various risks and uncertainties that may cause actual results to differ significantly from forward-looking statements[121]. - The unemployment rate remained low at 4.3% as of September 30, 2025, consistent with 4.1% as of December 31, 2024, indicating a stable labor market[168]. - National rent growth is projected at 1.8% for 2025, significantly lower than the aggressive growth seen in 2021 and 2022, with multifamily property values down 4.2% year-over-year as of December 2024[166]. Portfolio and Servicing - The managed portfolio totaled $157.9 billion as of September 30, 2025, up 4% from $152.3 billion in the same quarter last year, including a loan servicing portfolio of $139.3 billion[170][173]. - The total servicing portfolio grew by 4% to $139,331,678,000 as of September 30, 2025, compared to $134,080,546,000 in 2024[233]. - As of September 30, 2025, the total risk-sharing servicing portfolio increased to $71.02 billion from $66.14 billion in 2024, representing an increase of approximately 7.0%[291]. Cash Flow and Financing - Net cash used in operating activities for the nine months ended September 30, 2025, was $(1,467,679,000), a 266% increase in cash outflow compared to $(401,458,000) in 2024[201]. - Net cash provided by financing activities surged to $1,542,482,000, a 391% increase from $313,838,000 in the previous year[201]. - The company raised $200 million in equity capital for Debt Fund II, which will provide over $500 million of levered capital for transitional multifamily assets[170]. Goodwill and Impairment - Goodwill reported as of September 30, 2025, and December 31, 2024, is $868.7 million, with a goodwill impairment of $33.0 million in Q4 2024 attributed to the Capital Markets segment[161][165]. Regulatory and Compliance - The company is in compliance with all financial covenants related to warehouse facilities and notes payable as of September 30, 2025[289]. - The company is required to fund an additional $74.7 million in restricted liquidity over the next 48 months to meet collateral requirements[285].

Financial Performance - For the nine months ended September 30, 2025, Arhaus generated net revenue of $1,014.4 million, a gross margin of $397.2 million, and net income of $52.2 million[87]. - For the three months ended September 30, 2025, net revenue was $344.6 million, with a gross margin of $133.4 million and net income of $12.2 million[87]. - Net revenue increased by $90.3 million, or 9.8%, to $1,014.4 million for the nine months ended September 30, 2025, compared to $924.1 million for the same period in 2024[105]. - Gross margin increased by $34.7 million, or 9.6%, to $397.2 million for the nine months ended September 30, 2025, maintaining a gross margin percentage of 39.2%[106][107]. - Net and comprehensive income increased by $4.9 million to $52.2 million for the nine months ended September 30, 2025, compared to $47.3 million for the same period in 2024[112]. - The company reported a net income of $52.2 million for the nine months ended September 30, 2025, compared to $47.3 million in 2024, marking an increase of 6.9%[133][134]. Showroom Operations - As of September 30, 2025, Arhaus operated 103 Showrooms, maintaining the same total number as of December 31, 2024, with an increase in traditional Showrooms from 85 to 87[86]. - The total square footage of Showroom locations increased from 1,676 thousand square feet at December 31, 2024, to 1,718 thousand square feet by September 30, 2025[87]. - The company opened 7 new Showrooms from January 1, 2024, to September 30, 2025, while closing 1 permanently and relocating 6[101]. - Total showrooms at the end of the period increased to 103, up from 101 in the previous year[104]. Expenses and Costs - Selling, general and administrative (SG&A) expenses rose by $24.4 million, or 8.0%, to $328.5 million for the nine months ended September 30, 2025, with SG&A as a percentage of net revenue decreasing to 32.4%[108][109]. - Selling, general and administrative expenses (SG&A) are expected to increase as new Showrooms are opened and new product categories are developed[95]. - The gross margin is calculated as net revenue minus cost of goods sold, which includes various operational costs associated with merchandise[94]. Cash Flow and Investments - The company had cash and cash equivalents of $262.2 million as of September 30, 2025, with operating cash flows expected to meet working capital requirements for at least the next 12 months[121][122]. - For the nine months ended September 30, 2025, net cash provided by operating activities was $127.5 million, an increase from $115.4 million in the same period of 2024, representing a growth of 10.1%[133][134]. - Net cash used in investing activities for the nine months ended September 30, 2025, was $59.7 million, a decrease from $88.7 million in 2024, reflecting a reduction of 32.8%[136][137]. - Total capital expenditures, net of landlord contributions, decreased by $18.4 million to $42.9 million for the nine months ended September 30, 2025, compared to $61.3 million in 2024[139]. - The company anticipates total capital expenditures, net of landlord contributions, to be between $65 million and $75 million in fiscal year 2025, primarily for opening new Showrooms[140]. - Net cash used in financing activities was $2.9 million for the nine months ended September 30, 2025, significantly lower than $72.1 million in 2024, indicating a reduction of 96.0%[141][142]. Tax and Interest - The effective tax rate increased to 26.6% for the nine months ended September 30, 2025, compared to 23.1% for the same period in 2024[111]. - Interest income, net decreased to $2.1 million for the nine months ended September 30, 2025, compared to $2.6 million for the same period in 2024[110]. Strategic Initiatives - The company is undergoing a multi-year transformation with an expected investment of approximately $30 million for technology upgrades, including a new ERP system[125]. - The company emphasizes a direct-to-consumer approach, sourcing products directly from factories to offer exclusive assortments at attractive values[84]. - Demand comparable growth is a key performance indicator, reflecting year-over-year percentage changes in demand from comparable Showrooms and eCommerce[91]. Financial Instruments and Risks - The company does not currently use derivative instruments to manage foreign currency exchange risk or interest rate risk[146][147]. - Inflation has historically been managed through price increases, but the company cannot estimate future recovery of these costs[148]. - The company has no borrowings under the 2021 Credit Facility as of September 30, 2025, except for a $5.1 million irrevocable standby letter of credit[147].

Revenue Performance - Total revenues for the three months ended September 30, 2025, were $274.1 million, a decrease of $9.7 million, or 3.4%, compared to the same period in 2024[86]. - Total revenues for the six months ended September 30, 2025 were $523.6 million, a decrease of $27.3 million, or 5.0%, compared to the same period in 2024[102]. - North American OTC Healthcare segment revenues decreased by $9.1 million, or 3.8%, primarily due to declines in Eye & Ear Care and Women's Health categories[87]. - North American OTC Healthcare segment revenues decreased by $28.8 million, or 6.1%, primarily due to a decline in sales in the Eye & Ear Care category[104]. - International OTC Healthcare segment revenues decreased by $0.6 million, or 1.4%, mainly attributed to a decrease in Eye & Ear Care sales[88]. - International OTC Healthcare segment revenues increased by $1.5 million, or 1.9%, mainly driven by sales growth in the Dermatologicals and Analgesics categories[105]. Profitability Metrics - Gross profit for the three months ended September 30, 2025, decreased by $5.8 million, or 3.7%, with gross profit as a percentage of total revenues decreasing to 55.3% from 55.5%[90]. - Gross profit for the six months ended September 30, 2025 decreased by $11.5 million, or 3.8%, while gross profit as a percentage of total revenues increased to 55.7% from 55.1%[107]. - Contribution margin for the North American OTC Healthcare segment decreased by $0.8 million, or 0.8%, while the percentage increased to 41.8% from 40.5%[95]. - Contribution margin for the North American OTC Healthcare segment decreased by $2.3 million, or 1.2%, but increased as a percentage of revenues to 42.4% from 40.3%[112]. - Contribution margin for the International OTC Healthcare segment decreased by $2.3 million, or 12.4%, with the percentage decreasing to 38.1% from 42.8%[96]. Expenses and Financial Position - General and administrative expenses increased by $1.9 million to $28.0 million for the three months ended September 30, 2025, primarily due to higher professional fees and acquisition costs[97]. - General and administrative expenses increased to $56.5 million for the six months ended September 30, 2025, up from $55.0 million in 2024[114]. - Net cash provided by operating activities was $136.5 million for the six months ended September 30, 2025, an increase of $11.9 million compared to the same period in 2024[120]. - Cash and cash equivalents as of September 30, 2025 were $119.1 million, an increase of $21.2 million from March 31, 2025[119]. - Interest expense, net decreased to $20.2 million for the six months ended September 30, 2025, down from $25.4 million in 2024, with average indebtedness decreasing to $1.0 billion[116]. - The provision for income taxes for the six months ended September 30, 2025 was $41.2 million, with an effective tax rate of 31.5%, up from 20.5% in 2024[117]. - Net cash used in financing activities decreased by $5.5 million to $111.2 million for the six months ended September 30, 2025, primarily due to a $75.0 million decrease in debt repayments[122]. - As of September 30, 2025, the company had an aggregate of $1.0 billion of outstanding indebtedness, with no balance on the asset-based revolving credit facility and a borrowing capacity of $190.0 million[123]. - The company must maintain a fixed charge ratio greater than 1.0 to 1.0, and it was in compliance with applicable financial and restrictive covenants as of September 30, 2025[125]. - The company anticipates remaining in compliance with financial and restrictive covenants during the next twelve months[125]. Economic and Market Conditions - The company continues to face economic uncertainty, including supply chain constraints and inflation, which may impact product demand and costs[80]. - The company expects ongoing volatility in economic conditions, which could further affect its operations and financial performance[81]. - The company is exposed to risks including disruptions in supply, price increases for raw materials, and competition in the industry[131]. Foreign Currency Exposure - Approximately 16.0% of gross revenues for the three months ended September 30, 2025, were denominated in currencies other than the U.S. Dollar, indicating exposure to foreign currency exchange rates[135]. - A hypothetical 10.0% adverse change in foreign currency exchange rates would have resulted in a pre-tax income impact of approximately $1.3 million for the three months ended September 30, 2025[136]. Debt and Financing - The company has $400.0 million of 5.125% 2019 senior unsecured notes maturing on January 15, 2028, and $600.0 million of 3.750% 2021 senior unsecured notes maturing on April 1, 2031[127]. - The company experienced a decrease in shares surrendered as payment of tax withholding by $1.6 million[122]. - There were no material changes to critical accounting policies during the six months ended September 30, 2025[126].

Financial Performance - Total revenue for Q3 2025 was approximately $2.99 billion, a 23.3% increase from $2.42 billion in Q3 2024[3]. - Loss from operations for Q3 2025 was $129.3 million, compared to a loss of $48.4 million in Q3 2024[3][12]. - Net loss attributable to Oscar Health, Inc. was $137.5 million, or $(0.53) per diluted share, compared to a net loss of $54.6 million, or $(0.22) per diluted share, in Q3 2024[3][12]. - Adjusted EBITDA loss for Q3 2025 was $101.5 million, compared to a loss of $11.6 million in Q3 2024[3][12]. - Operating expenses for Q3 2025 totaled $3,115,234, a significant rise from $2,471,856 in Q3 2024, reflecting a 26% increase[21]. - Net income attributable to Oscar Health, Inc. for the three months ended September 30, 2025, was $(137,484) thousand, compared to $(54,388) thousand for the same period in 2024, indicating a significant increase in losses[36]. - The company reported earnings (loss) from operations of $(129,250) thousand for the three months ended September 30, 2025, compared to $(48,374) thousand in 2024, indicating a worsening operational performance[36]. Membership and Revenue Growth - Total membership reached 2,116,904 as of September 30, 2025, up from 1,654,284 in 2024, indicating strong growth in individual and small group offerings[4]. - Premium revenue for the nine months ended September 30, 2025, was $8,723,233, up 31.8% from $6,626,055 in the same period of 2024[21]. - Direct policy premiums for the three months ended September 30, 2025, reached $3,646,308 thousand, up from $2,687,883 thousand in 2024, representing a growth of approximately 35.8%[38]. Medical Loss Ratio and Expenses - Medical loss ratio for Q3 2025 was 88.5%, up from 84.6% in Q3 2024, primarily due to increased average market morbidity[3][12]. - Medical Loss Ratio (MLR) for Q3 2025 was 88.5%, compared to 84.6% in Q3 2024, indicating an increase in medical expenses relative to premiums[30]. - Medical expenses for the three months ended September 30, 2025, totaled $2,586,330 thousand, compared to $2,003,979 thousand in 2024, reflecting an increase of about 29.0%[38]. Cost Management - SG&A expense ratio improved to 17.5% in Q3 2025 from 19.0% in Q3 2024, attributed to better fixed cost leverage and disciplined cost management[3][12]. - SG&A expenses for the nine months ended September 30, 2025, were $1,538,836, up from $1,289,745 in the same period of 2024, reflecting a 19.3% increase[21]. - Selling, general, and administrative expenses for the three months ended September 30, 2025, were $521,592 thousand, compared to $459,522 thousand in 2024, marking an increase of approximately 13.5%[38]. Capital Structure and Guidance - Oscar Health entered into an exchange agreement to manage its capital structure, involving approximately $250 million of convertible senior notes[10][11]. - Full year 2025 revenue guidance is set between $12.0 billion and $12.2 billion, with a medical loss ratio expected between 86.0% and 87.0%[5]. - The company is focused on expanding margins and returning to profitability in 2026, supported by disciplined pricing and geographic expansion strategies[2]. Assets and Liabilities - Cash and cash equivalents as of September 30, 2025, were $2,148,865, an increase from $1,527,186 at the end of 2024[23]. - Total assets increased to $5,745,877 as of September 30, 2025, compared to $4,840,496 at the end of 2024, representing an 18.7% growth[23]. - Long-term debt rose to $686,294 as of September 30, 2025, compared to $299,555 at the end of 2024, indicating a significant increase in leverage[23]. - Net cash provided by operating activities for the nine months ended September 30, 2025, was $422,951, down from $631,373 in the same period of 2024[25]. Reinsurance and Interest Expense - Reinsurance recoverable as of September 30, 2025, was $159,391 thousand, down from $291,537 thousand as of December 31, 2024, indicating a decrease of approximately 45.5%[38]. - Interest expense for the nine months ended September 30, 2025, was $18,698 thousand, compared to $17,708 thousand in 2024, reflecting a rise of about 5.6%[36]. Stock-Based Compensation - Stock-based compensation for the nine months ended September 30, 2025, was $69,569 thousand, down from $83,969 thousand in 2024, representing a decrease of approximately 17.2%[36].

Financial Performance - Net revenue for Q3 2025 reached $212.6 million, a 6% increase compared to $201.4 million in Q3 2024[8] - Adjusted EBITDA for Q3 2025 was $34.4 million, representing 16.2% of revenue, an increase of 8% year-over-year[12] - The company reported a net loss of $64.4 million, or $4.30 per share, which is 30.3% of revenue, primarily due to higher litigation costs[9] - Net revenues for the three months ended September 27, 2025, were $212,558 thousand, an increase of 5.7% compared to $201,412 thousand for the same period in 2024[33] - The company reported a net loss of $64,446 thousand for the three months ended September 27, 2025, compared to a net income of $10,148 thousand for the same period in 2024[33] - Adjusted EBITDA for the three months ended September 27, 2025, was $34,354 thousand, which is 16.2% of net revenues, compared to 15.8% in the prior year[35] - The company reported a total operating loss of $(80,050) million for the three months ended September 27, 2025, compared to an operating income of $15,266 million for the same period in 2024[38] - Non-GAAP adjusted net income for the nine months ended September 27, 2025, was $41,221 thousand compared to $37,725 thousand for the same period in 2024[44] Segment Performance - Electronic Systems segment net revenue increased to $123.1 million, up from $115.4 million in Q3 2024, driven by military and space markets[14] - Structural Systems segment net revenue rose to $89.5 million, compared to $86.0 million in the same quarter last year, with operating income increasing to $11.9 million[18] - Electronic Systems segment revenues rose by 6.6% to $123,082 million, while Structural Systems segment revenues increased by 4.0% to $89,476 million for the three months ended September 27, 2025[38] - Segment operating income for Electronic Systems increased by 17.1% to $21,098 million, while Structural Systems segment operating income rose by 13.3% to $11,927 million for the three months ended September 27, 2025[38] - Non-GAAP adjusted operating income for Electronic Systems was $21,542 thousand, representing a 17.5% margin for the three months ended September 27, 2025, compared to 16.8% in 2024[42] - Non-GAAP adjusted operating income for Structural Systems was $14,298 thousand, with a margin of 16.0% for the three months ended September 27, 2025[42] Expenses and Costs - Corporate General and Administrative expenses surged to $113.1 million, or 53.2% of total revenue, due to litigation-related costs[19] - The company incurred litigation settlement and related costs of $99,675 thousand for the three months ended September 27, 2025[38] - The effective tax benefit rate for the three months ended September 27, 2025, was (22.3)%, compared to 11.3% for the same period in 2024[33] - The company incurred restructuring charges of $583 thousand for the three months ended September 27, 2025, down from $1,924 thousand in the same period of 2024[33] - Stock-based compensation expense for the three months ended September 27, 2025, included $0.1 million recorded as cost of sales, consistent with the same period in 2024[39] Backlog and Future Outlook - The Book to Bill ratio was strong at 1.6 times, establishing a new record for remaining performance obligations[4] - The company anticipates continued revenue growth in defense and commercial aerospace markets for the remainder of 2025[7] - Total backlog as of September 27, 2025, was $1,135,741 thousand, an increase from $1,060,819 thousand as of December 31, 2024[47] - The company's backlog consists of customer placed purchase orders and long-term agreements with expected delivery dates of 24 months or less, although specific backlog figures were not disclosed[28] Assets and Liabilities - Total assets increased to $1,248,570 thousand as of September 27, 2025, from $1,126,101 thousand as of December 31, 2024[31] - Current liabilities rose to $334,254 thousand as of September 27, 2025, compared to $175,474 thousand as of December 31, 2024[31] - Cash and cash equivalents increased to $50,918 thousand as of September 27, 2025, compared to $37,139 thousand as of December 31, 2024[31] Capital Expenditures - Total capital expenditures for the nine months ended September 27, 2025, amounted to $10,658 million, compared to $10,146 million for the same period in 2024[38]

Financial Performance - Enovis reported third-quarter net sales of $549 million, representing a 9% increase on a reported basis and a 7% increase on an organic basis compared to the same quarter in 2024[3]. - The company experienced a net loss of $571 million, equating to 104.0% of sales, primarily due to a non-cash goodwill impairment charge of $548 million[4]. - Adjusted EBITDA for the third quarter was $95 million, or 17.3% of sales, with adjusted net earnings per diluted share at $0.75[4][5]. - The gross profit margin for the third quarter was reported at 59.9%, an increase from 56.7% in the same quarter of 2024[20]. - Enovis Corporation reported a net loss of $570.9 million for the three months ended October 3, 2025, compared to a net loss of $31.3 million for the same period in 2024, reflecting a net loss margin of (104.0)%[22]. - Adjusted net income from continuing operations for the three months ended October 3, 2025, was $43.5 million, with an adjusted net income margin of 7.9%, compared to $41.0 million and 8.1% in the prior year[22]. - The company reported a net loss per share of $(9.99) for the three months ended October 3, 2025, compared to $(0.61) for the same period in 2024[22]. - Total net loss from continuing operations attributable to Enovis Corporation was $571.1 million for the three months ended October 3, 2025, compared to $33.8 million in the prior year[23]. - The company reported a net loss margin of (39.7)% for the nine months ended October 3, 2025, compared to (7.9)% for the same period in 2024[22]. - The company reported a net loss of $663.2 million for the nine months ended October 3, 2025, compared to a net loss of $121.6 million for the same period in 2024[31]. Sales Growth - Reconstructive sales grew 12% year-over-year on a reported basis and 9% organically, while Prevention & Recovery sales increased by 6% on a reported basis and 4% organically[3][6]. - Net sales for the three months ended October 3, 2025, were $548.9 million, an increase of 8.6% compared to $505.2 million for the same period in 2024[33]. - For the three months ended September 27, 2024, total net sales reached $505.2 million, reflecting an increase of 8.7% compared to the previous period[35]. - For the nine months ended October 3, 2025, total net sales increased to $1,672.3 million, showing a growth of 8.1%[35]. - Existing businesses contributed $33.0 million to the total sales growth, representing a 6.5% increase[35]. - The sales growth from existing businesses for the nine months was $113.1 million, which is a 7.3% increase[35]. - Foreign currency translation positively impacted sales by $14.1 million for the nine months, accounting for a 0.9% increase[35]. - Acquisitions contributed $2.8 million to the nine-month sales growth, representing a 0.2% increase[35]. - The impact of divestitures for the nine months was a decrease of $4.3 million, which is a 0.3% decline[35]. - The company experienced a foreign currency translation impact of $14.1 million for the nine months, contributing to overall sales growth[35]. Guidance and Strategic Focus - Enovis updated its 2025 revenue guidance to a range of $2.24-2.27 billion, reflecting a $15 million reduction due to the divestiture of the Dr. Comfort business unit[7]. - The adjusted EBITDA forecast for 2025 is now $395-405 million, up from the previous outlook of $392-402 million[7]. - Full-year adjusted earnings per share guidance was revised from $3.05-3.20 to $3.10-3.25[7]. - Enovis emphasized a focus on commercial execution, innovation, operational excellence, and financial discipline as strategic priorities for future growth[6]. Asset and Liability Changes - Total current assets increased to $1,280.1 million as of October 3, 2025, from $1,146.4 million as of December 31, 2024[29]. - Goodwill decreased to $1,218.7 million as of October 3, 2025, from $1,692.7 million as of December 31, 2024, indicating potential impairment[29]. - Cash and cash equivalents decreased to $33.6 million as of October 3, 2025, from $48.2 million at the beginning of the period[31]. - Total liabilities increased to $2,409.7 million as of October 3, 2025, compared to $2,154.4 million as of December 31, 2024[29]. - The company reported a total equity of $2,023.7 million as of October 3, 2025, down from $2,564.3 million as of December 31, 2024[29]. Impairment and Restructuring Charges - The company incurred a goodwill impairment charge of $548.4 million for the three months ended October 3, 2025, with total restructuring charges of $3.4 million during the same period[22][25]. - Strategic transaction costs related to the Lima Acquisition amounted to $9.2 million for the three months ended October 3, 2025, compared to $17.5 million for the same period in 2024[26]. - Enovis Corporation recognized $45.8 million for the net present value of royalty interest purchases, which will be paid over nine years, for the nine months ended October 3, 2025[26].

Financial Performance - Total revenue for Q3 2025 was $580.4 million, a 32.5% increase from $437.9 million in Q3 2024[2] - Net income for Q3 2025 reached $6.9 million, up 94.1% from $3.5 million in Q3 2024[2] - Adjusted EBITDA for Q3 2025 was $38.2 million, reflecting a 61.6% increase compared to $23.6 million in Q3 2024[3] - Operating income for Q3 2025 was $14,403,000, compared to $5,813,000 in Q3 2024, reflecting a 147.5% increase[26] - Net income attributable to Privia Health Group, Inc. for Q3 2025 was $6,861,000, up from $3,535,000 in Q3 2024, representing a 94.5% increase[26] - The adjusted net income for the three months ended September 30, 2025, was $37.3 million, compared to $25.1 million in 2024, representing a growth of 48.9%[41] - The adjusted net income per share attributable to Privia Health Group, Inc. stockholders was $0.30 for the three months ended September 30, 2025, compared to $0.21 in 2024, an increase of 42.9%[41] Revenue Growth - Practice collections for Q3 2025 totaled $940.4 million, a 27.1% increase from $739.9 million in Q3 2024[5] - The company raised its full-year 2025 guidance for practice collections to between $3,450 million and $3,500 million[13] - Capitated revenue for Q3 2025 was $90,906,000, a significant increase of 70.2% from $53,393,000 in Q3 2024[31] - The company experienced a 33.5% increase in total revenue for the nine months ended September 30, 2025, reaching $1,581,669,000 compared to $1,275,490,000 in 2024[31] - For the three months ended September 30, 2025, the revenue was $580.4 million, an increase from $437.9 million in the same period of 2024, representing a growth of 32.4%[38] - The practice collections for the nine months ended September 30, 2025, totaled $2,601.9 million, up from $2,175.6 million in 2024, indicating a growth of 19.5%[34] Provider and Attributed Lives Growth - Implemented providers increased by 13.1% to 5,250 in Q3 2025 from 4,642 in Q3 2024[3] - Attributed lives reached 1,406,000 as of September 30, 2025, compared to 1,247,000 in 2024, marking an increase of 12.7%[34] Asset and Cash Position - Cash and cash equivalents at September 30, 2025, were $441.4 million, with no debt reported[12] - The company expects to end FY 2025 with at least $410 million in cash and equivalents after the ACO transaction[15] - Total current assets increased to $970,926,000 as of September 30, 2025, compared to $834,823,000 at the end of 2024, a growth of 16.3%[28] - Total assets rose to $1,350,987,000 as of September 30, 2025, up from $1,135,783,000 at the end of 2024, marking an increase of 18.9%[28] - Cash and cash equivalents decreased to $441,352,000 from $491,149,000, a decline of 10.2%[30] - The company reported a net cash provided by operating activities of $35,904,000 for the nine months ended September 30, 2025, compared to $34,484,000 for the same period in 2024[30] Margin Improvements - The platform contribution margin improved to 56.3% for the three months ended September 30, 2025, compared to 49.6% in 2024[35] - The care margin for the three months ended September 30, 2025, was $125.2 million, an increase from $101.4 million in 2024, reflecting a growth of 23.5%[38] - The adjusted EBITDA margin for the three months ended September 30, 2025, was 30.5%, compared to 23.3% in 2024, showing an improvement of 7.2 percentage points[35] ACO and Shared Savings - Privia's ACOs achieved shared savings of $234.1 million in the MSSP for 2024, a 32.6% increase from 2023[8] - The company signed an agreement to acquire an ACO business from Evolent Health, which will add over 120,000 attributed lives[9] Unpaid Medical Claims - The balance for unpaid medical claims under at-risk capitation arrangements increased to $76,434,000 as of September 30, 2025, from $75,077,000 in 2024[32]